Exelixis, Inc. (NASDAQ:EXEL) reiterated its slate of activities in conjunction with the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 1-5, 2012, in Chicago, Illinois. Clinical data for cabozantinib will be featured in four oral presentations, four poster discussion presentations, and one general poster presentation. The company will also host an investor briefing that will be webcast live on Monday, June 4, 2012.

The full roster of cabozantinib data presentations expected at the meeting appears below (all times Central Daylight). As data are presented at the meeting, the accompanying presentations and/or posters will be made available online via the Events page under Resources on www.exelixis.com.

Oral Presentations
  • "Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC)" (Abstract #4504)Dr. Toni K. Choueiri, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, MAOral Abstract Session: Genitourinary Cancer (Nonprostate)Saturday, June 2; 4:15 p.m.
  • "Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT)" (Abstract #4007)Dr. Chris Verslype, Hepatology, University Hospitals Gasthuisberg, BelgiumOral Abstract Session: Gastrointestinal (Noncolorectal) CancerSaturday, June 2; 5:15 p.m.
  • "An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline" (Abstract #5508)Dr. Patrick Schöffski, Department of General Medical Oncology, Catholic University Leuven, BelgiumClinical Science Symposium: Targeting Therapeutics for Thyroid CancersMonday, June 4; 11:30 a.m.
  • "Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE)" (Abstract #4513)Dr. Matthew R. Smith, Massachusetts General Hospital Cancer Center, Boston, MAOral Abstract Session: Genitourinary Cancer (Prostate)Tuesday, June 5; 11:00 a.m.

Poster Discussion Presentations
  • "Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT)" (Abstract #535; Poster Board #25)Dr. Eric P. Winer, Dana-Farber Cancer Institute, Boston, MAPoster Discussion Session: Breast Cancer-HER2/ERSaturday, June 2; 1:15 p.m. - 5:15 p.m. (discussion to follow)
  • "Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT)" (Abstract #8531; Poster Board #20)Dr. Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZPoster Discussion Session: Melanoma/Skin CancersSaturday, June 2; 1:15 p.m. - 5:15 p.m. (discussion to follow)
  • "Investigator sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: A dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases" (Abstract #4566; Poster Board #20)Dr. Richard J. Lee, Massachusetts General Hospital Cancer Center, Boston, MAPoster Discussion Session: Genitourinary (Prostate) CancerMonday, June 4; 8:00 a.m. - 12:00 p.m. (discussion to follow)
  • "Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT)" (Abstract #7514; Poster Board #4)Dr. Beth A. Hellerstedt, US Oncology Research, LLC, McKesson Specialty Health, The Woodlands, TX, and Texas Oncology, Central Austin Cancer Center, Austin, TXPoster Discussion Session: Lung Cancer - Non-small Cell MetastaticTuesday, June 5; 8:00 a.m. - 12:00 p.m. (discussion to follow)

Poster Presentation
  • "Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC)" (Abstract #5547; Poster Board #22G)Dr. Maria E. Cabanillas, University of Texas MD Anderson Cancer Center, Houston, TXGeneral Poster Session: Head and Neck CancerSaturday, June 2; 1:15 p.m. - 5:15 p.m.

Details on May 16 th Release of 2012 ASCO Annual Meeting Abstracts

The 2012 ASCO Annual Meeting abstracts featuring cabozantinib will be posted publicly on www.asco.org today, Wednesday, May 16, 2012, at 6:00 p.m. EDT. These abstracts were submitted to ASCO in early 2012 and do not incorporate data and new findings generated since that time. The latest and most up-to-date clinical data will be delivered during the investigators’ presentations at the meeting itself, at the dates and times listed above.

Investor Briefing at the 2012 ASCO Annual Meeting

Exelixis will hold an investor briefing that will be webcast live on Monday, June 4, 2012, from 6:30-8:30 p.m. CDT. During the briefing, Exelixis management and other presenters will review and provide context for the latest clinical data for cabozantinib in medullary thyroid cancer, castration-resistant prostate cancer, and other tumor types, as presented at the ASCO Annual Meeting. In addition to Exelixis management, participants in the briefing will include:
  • Dr. Jose Baselga, Massachusetts General Hospital Cancer Center, Boston, MA
  • Dr. Toni Choueiri, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA
  • Dr. Karim Fizazi, Institut Gustave Roussy, Paris, France
  • Dr. Daniel George, Duke University Medical Center, Durham, NC
  • Dr. Patrick Schöffski, Catholic University Leuven, Belgium
  • Dr. Steven Sherman, MD Anderson Cancer Center, Houston, TX
  • Dr. Matthew Smith, Massachusetts General Hospital Cancer Center, Boston, MA

The webcast will be accessible via the Event Calendar page under Investors at www.exelixis.com.

An archived replay of the webcast will be available on the Event Calendar page under Investors at www.exelixis.com and audio-only via phone until 11:59 p.m. EDT/8:59 p.m. PDT on July 11, 2012. Access numbers for the audio-only phone replay are: 888-286-8010 (domestic) and 617-801-6888 (international); the passcode is 35434695.

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib (XL184), its most advanced product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, broadly-active, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at http://www.exelixis.com.

Copyright Business Wire 2010